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Background. Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introduced in Kenya in July 2014 and is recom-
mended to infants as oral doses at ages 6 and 10 weeks. A multisite study was established in 2 population-based surveillance sites to 
evaluate vaccine impact on the incidence of rotavirus-associated hospitalizations (RVHs).
Methods. Hospital-based surveillance was conducted from January 2010 to June 2017 for acute diarrhea hospitalizations among 
children aged <5 years in 2 health facilities in Kenya. A controlled interrupted time-series analysis was undertaken to compare 
RVH pre– and post–vaccine introduction using rotavirus-negative cases as a control series. The change in incidence post–vaccine 
introduction was estimated from a negative binomial model that adjusted for secular trend, seasonality, and multiple health worker 
industrial actions (strikes).
Results. Between January 2010 and June 2017 there were 1513 and 1652 diarrhea hospitalizations in Kilifi and Siaya; among 
those tested for rotavirus, 28% (315/1142) and 23% (197/877) were positive, respectively. There was a 57% (95% confidence interval 
[CI], 8–80%) reduction in RVHs observed in the first year post–vaccine introduction in Kilifi and a 59% (95% CI, 20–79%) reduction 
in Siaya. In the second year, RVHs decreased further at both sites, 80% (95% CI, 46–93%) reduction in Kilifi and 82% reduction in 
Siaya (95% CI. 61–92%); this reduction was sustained at both sites into the third year.
Conclusions. A substantial reduction in RVHs and all-cause diarrhea was observed in 2 demographic surveillance sites in Kenya 
within 3 years of vaccine introduction.
Keywords.  rotavirus vaccine; interrupted time series; control; vaccine impact.
Rotavirus is a major contributor to severe diarrhea illness and 
related mortality, especially in low- and middle-income coun-
tries [1–3]. Global estimates suggest that, in 2013, rotavirus 
accounted for 215  000 or 3.4% of all deaths in children aged 
less than 5 years [4]. In 2009, the World Health Organization 
recommended that all countries, especially those with high 
diarrhea-associated child mortality rates, implement rotavirus 
immunization programs [5]. Kenya adopted this recommenda-
tion in July 2014 [6, 7]. Since then, 2 doses of live-attenuated rota-
virus vaccine (Rotarix), in addition to oral polio, pneumococcal 
conjugate, and pentavalent vaccines, have been recommended 
to children in Kenya, targeted at 6 and 10 weeks of life, as part 
of the routine child immunization program [8, 9]. It was esti-
mated that introduction of this vaccine in Kenya would avert 
over 60  000 deaths and over 200  000 hospitalizations among 
children aged younger than 5  years during the first 20  years 
of introduction [10]. Following vaccine introduction, we used 
demographic and hospital data from 2 population-based sur-
veillance sites in Kenya to estimate the impact of the program 
on rotavirus hospitalizations in children younger than 5 years.
METHODS
Geographical Location
The study was conducted in 2 regions with established dem-
ographic surveillance systems (DSSs): the Kilifi Health and 
Demographic Surveillance System (Kilifi HDSS) [11], which is 
located on the Kenyan coast, and the Kenya Medical Research 
Institute (KEMRI) and the Centers for Disease Control and 
Prevention (CDC) Health and Demographic Surveillance 
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System (Siaya HDSS) [12] in rural western Kenya near Lake 
Victoria. Hospitalization, diarrhea, and rotavirus counts for 
children under 5 years of age were obtained from 2 govern-
ment hospitals: Kilifi County Hospital located in the Kilifi 
HDSS and Siaya County Referral Hospital located in the Siaya 
HDSS.
Vaccine Introduction and Coverage
Rotavirus vaccine was introduced into the childhood vacci-
nation program in both Kilifi and Siaya counties in July 2014. 
Children who were aged 6 weeks or younger or born after the 
start of the rotavirus immunization program were eligible to re-
ceive 1 dose at 6 weeks and 1 dose at 10 weeks, although vaccine 
stock-outs in November and December 2014 kept some eligible 
children from receiving vaccine. There was no catch-up cam-
paign in either Kilifi or Siaya.
In the Kilifi HDSS, vaccinations have been recorded com-
prehensively since 2008 through a network of approximately 30 
health facilities (both private and public) (Supplementary Figure 
1), as part of the Kilifi Vaccine-Monitoring Study (KiVMS) 
[13]. In the Siaya HDSS, over 20 health facilities administer 
vaccines to children (Supplementary Figure 2); since 2007, im-
munization data have been collected for children aged less than 
5 years during household data collection rounds, which occur 
2–3 times per year [12]. In addition, the vaccination status of 
children enrolled in the rotavirus surveillance at Siaya County 
Referral Hospital is recorded at the time of hospital admission. 
In both sites, card-confirmed vaccine information was captured 
by the field staff.
Rotavirus Surveillance
In 2009, to prepare for vaccine introduction [12, 14], rotavirus 
surveillance was intensified at Siaya County Referral Hospital 
among children aged less than 5  years who presented with 3 
or more loose stools within a 24-hour period and 1 or more 
vomiting episodes. In Kilifi, rotavirus surveillance was initi-
ated in late 2009 in inpatient children aged less than 13 years 
with 3 or more loose stools within a 24-hour period. Parents of 
eligible children were briefed on the potential risks and bene-
fits of the study before being asked to give consent by the study 
team. Stool samples were collected from eligible children whose 
parents provided voluntary informed consent and tested for ro-
tavirus antigen by enzyme-linked immunosorbent assay, as de-
scribed previously [14, 15].
Surveillance was interrupted by 12 strikes, including 7 before 
and 5 after rotavirus vaccine introduction, by different cadres of 
healthcare workers as indicated in Supplementary Table 1.
Statistical Analysis
We used a controlled interrupted time-series analysis in which 
rotavirus-negative diarrhea hospitalizations acted as the control 
series to compare monthly rotavirus-associated hospitalizations 
(RVHs) before and after rotavirus vaccine introduction in chil-
dren younger than 5 years of age. Specifically, RVHs from the 
period 54  months prior to (January 2010 to June 2014)  were 
compared with hospitalizations from the period 36  months 
after (July 2014 to June 2017) vaccine introduction at each fa-
cility. For a month in which less than 100% of diarrhea cases 
were tested for rotavirus, the number of rotavirus-positive cases 
was scaled by multiplying the total number of diarrhea cases by 
the proportion who were rotavirus positive among those tested 
in that month.
A negative binomial regression was used to estimate the 
change in rotavirus hospitalizations in the first year (July 2014–
June 2015), second year (July 2015–June 2016), and third year 
(July 2016–June 2017)  post–vaccine introduction. The model 
included rotavirus-negative diarrhea (the control series) as an 
offset and calendar month and health worker industrial actions 
as covariates. Lag-1 Newey-West standard errors were used 
to adjust for autocorrelation [16]. A similar analysis was con-
ducted for all-cause diarrhea using non–diarrhea hospitaliza-
tions as the control series.
For the analysis of rotavirus-positive diarrhea, a sensitivity 
analysis was conducted using a synthetic control [17–19] in 
the regression model instead of rotavirus-negative cases. The 
synthetic control was generated by weighting 3 conditions 
(rotavirus-negative diarrhea, pneumonia, malaria)—using the 
SYNTH [20] command in Stata—so that their sum closely re-
sembled the prevaccine rotavirus-positive time series.
All statistical analyses were conducted using Stata13.1 soft-
ware (Stata Corporation). All datasets, Stata files, and related 
documentation are available on an online data repository 
(https://doi.org/10.7910/DVN/PH4COG) [21].
Ethics Review
Ethical approval to conduct this study was granted by the KEMRI 
Scientific and Ethics Review Unit (SERU; SSC 3049)  and the 
CDC's institutional review board (protocol 6968).
RESULTS
Incidence and Seasonality
During the study period, there were 1513 and 1652 diarrhea 
hospitalizations in Kilifi County Hospital and Siaya County 
Referral Hospital, respectively. In Kilifi, 1142 (75.5%) of the di-
arrhea cases were tested, and among those tested, 315 (27.6%) 
were positive for rotavirus. In Siaya, 877 (53.1%) were tested 
and 197 (22.5%) were positive for rotavirus.
The proportion of children living in the study areas who re-
ceived rotavirus vaccine increased with time. Between 2014 
(year of introduction) and 2017, the proportion of those aged 
less than 1 year with at least 1 dose increased from 31% to 73% 
in Kilifi and from 16% to 75% in Siaya; the proportion who were 
fully vaccinated (2 doses) in 2017 was 65% in Kilifi and 62% 
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in Siaya. The highest coverage among infants was observed in 
2016. Among children aged 12–23 months, the proportion with 
at least 1 dose increased from 0% to 86% in Kilifi and from 0% 
to 94% in Siaya; coverage with 2 doses in 2017 was 84% and 
92%, respectively (Figure 1). The lowest proportions of vac-
cinated children were observed in 2014 across both sites due 
to vaccine roll-out in midyear and the unexpected stock-out. 
Among vaccinated children, the median age at receipt of the 
first dose was 6 weeks (interquartile range [IQR], 6–7 weeks) 
in Kilifi and 6 weeks (IQR, 6–7 weeks) in Siaya; median age at 
receipt of the second dose was 10 weeks (IQR, 10–13 weeks) in 
Kilifi and 10 weeks (IQR, 10–12 weeks) in Siaya.
Across the 2 DSSs, overall diarrheal illness and rotavirus-
specific illness displayed seasonal patterns, which were damp-
ened after the introduction of the vaccine (Figure 2). Siaya 
generally recorded higher diarrhea and rotavirus-associated 
diarrhea incidences compared with Kilifi in the prevaccination 
era (Tables 1 and 2). In Kilifi, the highest numbers of rotavirus 
cases were recorded from April/May to September/November 
of the same year (Figure 2A). In Siaya, the RVH season began 
earlier in the year, usually in January /February (Figure 2B). At 
both sites, there was a declining trend in annual incidence of 
diarrhea and RVHs that began prior to the rotavirus immuni-
zation program and continued following the introduction of 
Figure 1. Proportion of children aged less than 5 years who had received 1 or 2 doses of rotavirus vaccine between 2014 and 2017 in Kilifi and Siaya demographic surveil-
lance sites. Abbreviation: HDSS, Health and Demographic Surveillance System; n, number of children vaccinated.
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Table 1. Monthly Diarrhea and Rotavirus Counts and Incidence Rates per 100  000 Children per Year by Site Prior to Rotavirus Vaccine Introduction 
(January 2010–June 2014)
Kilifi Siaya
Person-
years Diarrhea
Rotavirus 
(Observed)
Rotavirus 
(Scaled)
Diarrhea 
Incidence
Rotavirus 
Incidence
Person-
years Diarrhea
Rotavirus 
(Observed)
Rotavirus 
(Scaled)
Diarrhea 
Incidence
Rotavirus 
Incidence
January 20 041 90 19 22 449 110 8169 218 22 49 2669 600
February 20 041 86 12 16 429 80 8169 220 39 70 2693 857
March 20 041 103 15 19 514 95 8169 136 25 51 1665 624
April 20 041 113 21 29 564 145 8169 116 16 30 1420 367
May 20 041 125 22 29 624 145 8169 160 24 37 1959 453
June 20 041 158 37 47 788 235 8169 164 9 18 2008 220
July 16 055 118 38 52 735 324 6769 111 8 13 1640 192
August 16 055 78 39 46 486 287 6769 73 8 13 1078 192
September 16 055 65 25 33 405 206 6769 65 9 12 960 177
October 16 055 58 12 14 361 87 6769 70 7 11 1034 163
November 16 055 68 5 6 424 37 6769 73 6 12 1078 177
December 16 055 40 4 6 249 37 6769 81 9 19 1197 281
Rotavirus incidence rates are scaled as described in the Methods section.
Figure 2. Monthly counts of diarrhea and rotavirus-positive cases in Kilifi (A) and Siaya (B) from January 2010 to June 2017. Strikes by health workers are indicated by gray 
shading, and the start of rotavirus vaccination in Kenya (July 2014) is indicated by an arrow.
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vaccine (2015–2017). During the years affected by industrial ac-
tions of health workers (Supplementary Table 1) lower rotavirus 
incidence rates were recorded at both sites (Table 2).
Impact of Vaccine Using a Rotavirus-Negative Control Series
In Kilifi, we observed reduced rates of RVHs among Kilifi HDSS res-
ident children younger than 5 years throughout the postvaccination 
period (Table 3 and Figure 3). When compared with rates from 
the prevaccine era, reductions were observed during the first year 
(57%; 95% confidence interval [CI], 8.0–80.0%), the second year 
(80%; 95% CI, 46–93%), and the third year (76%; 95% CI, 56–87%) 
(Supplementary Figure 3a). Similarly, in Siaya, there were reduc-
tions in the first year (59%; 95% CI, 20–79%), second year (82%; 
95% CI, 61–92%), and the third year (81%; 95% CI, 7–96%) post–
vaccine introduction (Supplementary Figure 3b).
Impact of Vaccine on All-Cause Diarrhea
When examining trends in all-cause diarrhea using non–diar-
rhea hospitalizations as the control series, significant reductions 
were observed at both sites in post–vaccine introduction years 
(Table 3), although by a smaller magnitude compared with re-
ductions in RVHs. In Kilifi, the impact of the vaccine on all-
cause diarrhea increased from 41% (95% CI, 16–59%) in the 
first year to 48% (95% CI, 40–55%) and 46% (95% CI, 34–55%) 
in the second and third year, respectively (Supplementary 
Figure 3e). In Siaya, there was a 41% (95% CI, 27–52%) reduc-
tion in all-cause diarrhea in the first year followed by 60% (95% 
CI, 43–72%) in the second year and 62% (95% CI, 38–77%) in 
the third year (Supplementary Figure 3f).
Impact of the Vaccine on Rotavirus-Associated Hospitalizations Using 
Synthetic Controls
The associated weights for each component of the synthetic con-
trol are shown in Supplementary Table 2 and the results of vaccine 
impact analysis in Supplementary Table 3 and Supplementary 
Figure 3. Vaccine impact estimates from this analysis are similar 
to those presented in Table 3, except that the estimate for the last 
year in Kilifi was slightly lower than the corresponding estimate 
in Table 3. In Kilifi, the impact of the vaccine was 67% (95% CI, 
27–85%) in the first year, 86% (95% CI, 64–94%) in the second 
year, and 69% (95% CI, 45–83%) in the third year. Similarly, in 
Siaya, vaccine impact increased from 68% (95% CI, 33–84%) in 
the first year to 89% (95% CI, 68–96%) in the second year and 
82% (95% CI, 8–96%) in the third year.
DISCUSSION
We present results of an evaluation of the impact of rota-
virus vaccine in Kenya using data from 2 population-based 
Table 2. Annual Diarrhea and Rotavirus Incidence Rates per 100 000 Children Under 5 Years in Kilifi and Siaya, Kenya
Kilifi Siaya
Year
Population 
Estimate Diarrhea
Rotavirus 
(Observed)
Rotavirus 
(Scaled)a
Diarrhea 
Incidence
Rotavirus 
Incidence
Population 
Estimate Diarrhea
Rotavirus 
(Observed)
Rotavirus 
(Scaled)a 
Diarrhea 
Incidence
Rotavirus 
Incidence
2010 47 746 319 70 93 668 195 21 885 500 78 124 2285 567
2011 48 083 323 74 90 672 187 20 953 446 53 107 2129 511
2012 48 412 213 56 70 440 145 19 947 201 26 50 1008 251
2013 48 414 140 31 42 289 87 18 439 218 21 45 1182 244
2014 47 835 196 31 40 410 84 16 803 162 7 13 964 77
2015 47 943 157 39 51 327 106 14 613 71 8 8 486 55
2016 46 109 116 12 13 252 28 12 806 39 2 2 305 16
2017 23 310 49 2 3 210 13 10 891 15 2 2 138 18
aRotavirus incidence rates are scaled as described in the Methods section.
Table 3. Incidence Rate Ratios Comparing Rotavirus and Diarrhea Incidence Pre– (January 2010–June 2014)  and Post–Vaccine (July 2014–June 
2017) Introduction in a Vaccine Impact Study in Kenya, 2010–2017
Rotavirus All-cause Diarrhea
Post–Vaccine Period IRR 95% CI P value IRR 95% CI P value
Kilifi       
 July 2014–June 2015 0.43 .20–.92 .031 0.59 .41–.84 .003
 July 2015–June 2016 0.20 .07–.54 .002 0.52 .45–.60 <.001
 July 2016–June 2017 0.24 .13–.44 <.001 0.54 .45–.66 <.001
Siaya       
 July 2014–June 2015 0.41 .21–.80 .009 0.59 .48–.73 <.001
 July 2015–June 2016 0.18 0.08–0.39 <.001 0.40 .28–.57 <.001
 July 2016–June 2017 0.19 .04–.93 .040 0.38 .23–.62 <.001
See the Methods section for statistical details.
Abbreviations: CI, confidence interval; IRR, incidence rate ratio.
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surveillance systems. Kenya introduced Rotarix vaccine into the 
national program as a 2-dose schedule (6 and 10 weeks of age). 
We observed that most vaccinated children at both sites received 
either 1 or both doses of the vaccine within 3 weeks of the re-
commended time of vaccination. We estimated the impact of 
the vaccine on RVHs using non–rotavirus hospitalizations and 
synthetic controls to control for any secular trends unrelated to 
the vaccine. Despite differences in the incidence of rotavirus di-
sease in Kilifi and Siaya, as observed in this study and previous 
studies [15, 22], the impact of vaccination was similar at both 
sites. In the first year post–vaccine introduction, RVHs declined 
by close to 60% in both Kilifi and Siaya, and all-cause diarrhea 
declined by over 40% at both sites. In the second year of vac-
cination, RVHs further declined by over 80%, and this decline 
was sustained into the third post–vaccine introduction year with 
increasing coverage. Similarly, the positive impact of the vaccine 
on all-cause diarrhea increased in the second and third years to 
as high as 60% reduction, thus providing clear evidence of the 
substantial public health value of rotavirus immunization. These 
reductions suggest that vaccination of children aged less than 
2 years, who are most likely to transmit rotavirus, optimizes di-
rect and indirect protection against severe diarrheal infections.
Our estimates of rotavirus vaccine impact in the first year of 
vaccination are consistent with estimates from other African 
studies, which have ranged between 54% and 61% reduction for 
RVHs and between 43% and 48% for all-cause diarrhea hospi-
talizations [23, 24]. The same studies reported increasing impact 
in the second year of vaccination as was observed in our study.
Using the average of the 2013 Kilifi and Siaya rotavirus di-
sease incidence estimates (166 per 100  000 per year) to rep-
resent disease incidence in Kenya in the absence of rotavirus 
vaccination, and assuming an under-5 population size of 6 mil-
lion [25], an 80% vaccine impact equates to approximately 8000 
rotavirus-related hospitalizations prevented per year in Kenyan 
Figure 3. Monthly counts of rotavirus-positive cases (solid lines) and the number of cases (dashed lines) predicted by the model assuming no vaccine introduction. The 
vertical line indicates the time of vaccine introduction in Kenya (July 2014).
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children younger than 5 years. Over 20 years this corresponds 
to 160 000 hospitalizations prevented, which is similar to a pre-
vious estimate of 200 000 [10].
Our study was impacted by health worker industrial actions 
and a prevaccine secular trend in RVHs, possibly reflecting im-
proved sanitation and hygiene [26]. To mitigate against these 
potential sources of bias we included the monthly rotavirus 
negative cases (or synthetic controls) as an offset term in our 
regression model. Additionally, we excluded the longest strike 
period (July–December 2017) from our analysis. An important 
assumption of this analysis is that the rotavirus-negative count 
reflects the counterfactual trend in rotavirus-positive cases 
that would have been observed in the absence of vaccination. 
Another limitation we considered was that only a fraction (75% 
in Kilifi and 53% in Siaya) of eligible diarrhea cases were tested 
for rotavirus, which represents another potential source of bias. 
To adjust for this, we imputed the number of rotavirus cases 
by multiplying the number of diarrhea cases by the fraction 
that tested positive. This imputation assumes that the fraction 
of rotavirus-positive cases is the same in those tested as it is in 
those who were not tested and may itself introduce bias, partic-
ularly if the fraction tested changes over time.
In conclusion, results from this study suggest that the 
burden of rotavirus and all-cause diarrhea declined substan-
tially in Kenyan children in 2 regions of Kenya after rotavirus 
vaccine introduction. The estimates from this study represent 
total impact, indicating potential herd effects of the vaccine. 
Our estimates of vaccine impact on rotavirus and all-cause 
diarrhea were consistent across the 2 study sites and are con-
sistent with findings from other African countries. These re-
sults contribute to the global estimates of rotavirus vaccine 
impact, especially in low- and middle-income countries, and 
will likely inform future decisions by policy makers on rota-
virus vaccination.
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